Thyroid autonomy: Mechanism and clinical effects

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 12, 1996, Pages 4187-4193

  Dremier, S ^a   Coppee F ^a   Delange, F ^a   Vassart, G ^a   Dumont, J E ^a   Van Sande, J ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; IODINE; SODIUM CHLORIDE; THYROTROPIN; THYROTROPIN RECEPTOR; HYDROGEN PEROXIDE;

ENDEMIC GOITER; HUMAN; HYPERTHYROIDISM; INDEPENDENCE; IODINATION; IODINE DEFICIENCY; MUTATION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; THYROID ADENOMA; THYROID FUNCTION; ANIMAL; CHEMICALLY INDUCED DISORDER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; THYROID GLAND;

ANIMALS; CYCLIC AMP; GOITER, ENDEMIC; HUMANS; HYDROGEN PEROXIDE; HYPERTHYROIDISM; IODINE; THYROID GLAND; THYROTROPIN;

EID: 0029838821     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.12.4187     Document Type: Review

References (74)

1. Adams DD, Kennedy TH, Stewart JC, Utiger RD, Vidor GI. 1974 Hyperthyroidism in Tasmania following iodide supplementation: measurements of thyroid-stimulating autoantibodies and thyrotropin. J Clin Endocrinol Metab. 41:221-228.
2. Bourdoux P, Ermans AM, Mukalay WA, Mukalay A, Filetti S, Vigneri R. 1996 Iodine-induced thyrotoxicosis in Kivu, Zaire. Lancet. 347:552-553.
3. Galofré JC, Fernandez-Calvet L, Rios M, Garcia-Mayor RVG. 1994 Increased incidence of thyrotoxicosis after iodine supplementation in an iodine sufficient area. J Endocrinol Invest. 17:23-27.
4. Kristensen HL, Vadstrup S, Knudsen N, Siersback-Nielsen K. 1995 Development of hyperthyroidism in nodular goiter and thyroid malignancies in an area of relatively low iodine intake. J Endocrinol Invest. 18:41-43.
5. Stewart JC, Vidor GI, Buttfield IH, Hetzel BS. 1971 Epidemic thyrotoxicosis in northern Tasmania: studies of clinical features and iodine nutrition. Aust NZ J Med. 3:203-211.
6. Todd CH, Allain T, Gomo ZAR, Hasler JA, Ndiweni M, Oken E. 1995 Increase in thyrotoxicosis associated with iodine supplements in Zimbabwe. Lancet. 346:1563-1564.
7. Vidor GI, Stewart JC, Wall JR, Wangel A, Hetzel BS. 1973 Pathogenesis of iodine-induced thyrotoxicosis: studies in Northern Tasmania. J Clin Endocrinol Metab. 37:901-909.
8. Dumont JE. 1971 The action of thyrotropin on thyroid metabolism. Vitam Horm. 29:287-412.
9. Laurent E, Mockel J, Van Sande J, Graff I, Dumont JE. 1987 Dual activation by thyrotropin of the phospholipase C and cAMP cascades in human thyroid. Mol Cell Endocrinol. 52:273-278.
10. Corvilain B, Laurent E, Lecomte M, Van Sande J, Dumont JE. 1994 Role of the cyclic adenosine 3′,5′-monophosphate and the phosphatidylinositol-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. J Clin Endocrinol Metab. 79:152-159.
11. Raspé E, Dumont JE. 1995 Tonic modulation of dog thyrocyte H2O2 generation and I-uptake by thyrotropin through the cyclic adenosine 3′,5′-monophosphate cascade. Endocrinology. 136:965-973.
12. Vassart G, Dumont JE. 1992 The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev. 13:596-611.
13. Roger PP, Hotimsky A, Moreau C, Dumont JE. 1982 Stimulation by thyrotropin, cholera toxin and dibutyryl cyclic AMP of the multiplication of differentiated thyroid cells in vitro. Mol Cell Endocrinol. 26:165-172.
14. Roger PP, Taton M, Van Sande J, Dumont JE. 1988 Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 66:1158-1165.
15. Dumont JE, Lamy F, Roger PP, Maenhaut C. 1992 Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev. 72:667-697.
16. Roger PP, Servais P, Dumont JE. 1983 Stimulation by thyrotropin and cyclic AMP of the proliferation of quiescent canine thyroid cells cultured in a defined medium containing insulin. FEBS Lett. 157:323-329.
17. Dumont JE, Jauniaux JC, Roger PP. 1989 The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci. 14:67-71.
18. Ledent C, Dumont JE, Vassart G, Parmentier M. 1992 Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J. 11:537-542.
19. Maenhaut C, Van Sande J, Libert F, et al. 1990 RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun. 173:1169-1178.
20. Michiels FM, Caillou B, Talbot M, et al. 1994 Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice. Proc Natl Acad Sci USA. 91:10488-10492.
21. Zakarija M, Jin S, McKenzie JM. 1988 Evidence supporting the identity in Graves' disease of thyroid-stimulating antibody and thyroid growth-promoting immunoglobulin G as assayed in FRTL5 cells. J Clin Invest. 81:879-884.
22. Van Sande J, Lamy F, Lecocq R, et al. 1988 Pathogenesis of autonomous thyroid nodules: in vitro study of iodine and adenosine 3′,5′-monophosphate metabolism. J Clin Endocrinol Metab. 66:570-579.
23. Landis CA, Masters SB, Spada A, pace AM, Bourne HR, Vallar L. 1989 GTPase inhibiting mutations activate the delta chain of Gs and stimulates adenylate cyclase in human pituitary tumors. Nature 340:692-696.
24. Lyons J, Landis CA, Harsh G, et al. 1990 Two G protein oncogenes in human endocrine tumors. Science. 249:655-659.
25. O'Sullivan C, Barton CM, Staddon SL, Brown CL, Lemoine NP. 1991 Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog. 4:345-349.
26. Suarez HG, Du Villard JA, Caillou B, Schlumberger M, Parmentier C, Monier R. 1991 gsp mutations in human thyroid tumours. Oncogene. 6:677-679.
27. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Engl J Med. 325:1688-1695.
28. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, Lefkowitz RJ. 1992 Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem. 267;1430-1433.
29. Lefkowitz RJ, Cotecchia S, Samana P, Costa T. 1994 Constitutive activity of receptors coupled to guanine nucleoticle regulatory proteins. Trends Pharmacol Sci. 14:303-307.
30. Parma J, Duprez L, Van Sande J, et al. 1993 Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 365:649-651.
31. Demeester-Mirkine N, Ermans AM. 1967 Euthyroid "hot" nodules: a physiological approach. In: Irvine WJ, ed. Thyrotoxicosis. Livingstone. 68-75.
32. Van Sande J, Mockel J, Boeynaems JM, Dor P, Andry G, Dumont JE. 1980 Regulation of cyclic nucleotide and prostaglandin formation in human thyroid tissues and in autonomous nodules. J Clin Endocrinol Metab. 50:776-785.
33. Kosugi S, Okajima F, Ban T, Hidaka A, Shenker A, Kohn LD. 1994 Substitutions of different regions of the third cytoplasmic loop of the TSH receptor have selective effects on constitutive TSH- and TSH receptor autoantibody-stimulated phosphoinositide and cAMP signal generation. Mol Endocrinol. 7:1009-1020.
34. Van Sande J, Swillens S, Gerard C, et al. 1995 In Chinese hamster ovary K1 cells dog and human thyrotropin receptors activate both the cyclic AMP and the phosphatidylinositol 4,5-bisphosphate cascades in the presence of thyrotropin and the cyclic AMP cascade in its absence. Eur J Biochem. 229:338-343.
35. Leclere J, Béné MC, Duprez A. 1984 Behavior of thyroid tissue from patients with Graves' disease in nude mice. J Clin Endocrinol Metab. 59:175-177.
36. Thomas JS, Leclere J, Hartemann P. 1982 Familial hyperthyroidism without evidence of autoimmunity. Acta Endocrinol (Copenh). 100:512-518.
37. Duprez L, Parma J, Van Sande J, et al. 1994 Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nature Genetics. 7:396-401.
38. Kopp P, Van Sande J, Parma J, et al. 1995 Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med. 19:150-154.
39. Parma J, Van Sande J, Swillens S, Tonacchera M, Dumont JE, Vassart G. 1995 Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3′,5′-monophosphate and inositol phosphate-Ca2+ cascades. Mol Endocrinol. 9:725-733.
40. Paschke R, Tonacchera M, Van Sande J, Parma J, Vassart G. 1994 Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab. 79:1785-1789.
41. Van Sande J, Parma J, Tonacchera M, Swillens S, Dumont JE, Vassart G. 1995 Genetic basis of endocrine disease. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab. 80:2577-2585.
42. Sheline GE, McCormack K. 1960 Solitary hyperfunctioning thyroid nodules. J Clin Endocrinol Metab. 20:1401-1410.
43. Corvilain B, Van Sande J, Dumont JE. 1988 Inhibition by iodide of iodide binding to proteins: the "Wolff-Chaikoff" effect is caused by inhibition of H2O2 generation. Biochem Biophys Res Commun. 154:1287-1292.
44. Laurent E, Mockel J, Takazawa K, Erneux C, Dumont JE. 1989 Stimulation of generation of inositol phosphates by carbamylcholine and its inhibition by phorbol esters and iodide in dog thyroid cells. Biochem J. 263:795-801.
45. Van Sande J, Grenier G, Willems C, Dumont JE. 1975 Inhibition by iodide of the activation of the thyroid cyclic 3′,5′-AMP system. Endocrinology. 96:781-786.
46. Panneels V, Van Sande J, Van den Bergen H, et al. 1994 Inhibition of human thyroid adenyl cyclase by 2-iodoaldehydes. Mol Cell Endocrinol. 106:41-50.
47. Maenhaut C, Roger PP, Reuse S, Dumont JE. 1991 Activation of the cyclic AMP cascade as an oncogenic mechanism: the thyroid example. Biochimie, 73:29-36.
48. Lacroix A, Bolté E, Tremblay J. 1992 Gastric inhibitory polypeptide-dependent cortisol hypersecretion - a new cause of Cushing's syndrome. N Engl J Med, 327:974-980.
49. Demeester-Mirkine N, Van Sande J, Corvilain B, Dumont JE. 1975 Benign thyroid nodule with normal iodide trap and defective organification. J Clin Endocrinol. 41:1169-1171.
50. Demeester-Mirkine N, Van Sande J. 1984 Iodide organification defect in a cold thyroid nodule: absence of iodide effect on cyclic AMP accumulation. Clin Endocrinol (Oxf). 20:473-479.
51. Field JB, Larsen R, Yamashita K, Mashiter K, Dekker A. 1973 Demonstration of iodide transport defect but normal iodide organification in nonfunctioning nodules of human thyroid glands. J Clin Invest. 52:2404-2410.
52. Thomas R. 1978 Logical analysis of systems comprising feedback loops. J Ther Biol. 73:631-656.
53. Müller WA. 1996 Pattern formation in the immortal hydra. TIG. 12:91-96.
54. Emrich D, Erlenmaier U, Pohl M, Luig H. 1993 Determination of the autonomously functioning volume of the thyroid. Eur J Nucl Med. 20:410-414.
55. Becker W, Wolf F. 1993 Risk of thyrotoxicosis in patients with autonomously functioning thyroid nodules. Exp Clin Endocrinol. 101:102-108.
56. Ermans AM, Camus M. 1972 Modifications of thyroid function induced by chronic administration of iodide in the presence of "autonomous" thyroid tissue. Acta Endocrinol. 70:463-475.
57. Surks MI, Ocampo E. 1996 Subclinical thyroid disease. Am J Med. 100:217-223.
58. Roti E, Vagenakis AG. 1996 Effects of iodide excess: clinical aspects. In: Braverman LE, Utiger RD, eds. The thyroid. A fundamental and clinical text. Philadelphia: Lippincott-Raven; 316-327.
59. Bray GA. 1968 Increased sensitivity of the thyroid in iodine-depleted rats to the goitrogenic effects of thyrotropin. J Clin Invest. 47:1640-1647.
60. Brabant G, Bergmann P, Kirsch CM, Köhrie J, Hesch RD, von zur Mühlen A. 1992 Early adaptation of thyrotropin and thyroglobulin secretion to experimentally decreased iodine supply in man. Metabolism. 41:1093-1096.
61. Jonckheer MH, Velkeniers B, Vanhaelst L, Van Blerk M. 1992 Further characterization of iodide-induced hyperthyroidism based on the direct measurement of intrathyroidal iodide stores. Nucl Med Commun. 13:114-118.
62. Als C, Listewnik M, Rösler H, Bartkowiak E. 1995 Immunogenic and non-immunogenic hyperthyroidism. Nuklear Medizin. 34:92-99.
63. Peter MJ, Gerber M, Studer H, Smeds S. 1985 Pathogenesis of heterogeneity in human multinodular goiter. J Clin Invest. 76:1992-2002.
64. Baltisberger BL, Minder CE, Bürgi H. 1995 Decrease of incidence of toxic nodular goiter in a region of Switzerland after full correction of mild iodine deficiency. Eur J Endocrinol. 132:546-549.
65. Peter HJ, Studer H, Forster R, Gerber H. 1982 The pathogenesis of "hot" and "cold" follicles in multinodular goiters. J Clin Endocrinol Metab. 55:941-946.
66. Delange F. 1974 Endemic goiter and thyroid function in Central Africa. In: Anonymous, ed. Monographs in pediatrics. Basel: Karger; 1-171.
67. Hetzel BS, Pandav CS. S.O.S. for a billion. In: Anonymous, ed. The conquest of iodine deficiency disorders. Dehli: Oxford University Press; 1-466.
68. Bürgi H, Supersaxo Z, Selz B. 1990 Iodine deficiency disease in Switzerland one hundred years after Theodor Kocher's survey: a historical review with some new goiter prevalence data. Acta Endocrinol (Copenh). 123:577-590.
69. UNICEF. 1995 The progress of nations. 1-54.
70. Dunn JT. 1994 The use of iodized oil and other alternatives for the elimination of iodine deficiency disorders. In: Hetzel BS, Pandav CS, eds. S.O.S. for a billion. The conquest of iodine deficiency disorders. New Dehli: Oxford University Press; 108-117.
71. Van Herle AJ, Vassart G, Dumont JE. 1979 Control of thyroglobulin synthesis and secretion. N Engl J Med. 301:307-314.
72. Glinoer D, de Nayer P, Delange F, et al. 1995 A randomized trial for the treatment of excessive thyroidal stimulation in pregnancy: maternal and neonatal effects. J Clin Endocrinol Metab. 80:258-269.
73. World Health Organization. 1996 Iodine. In: Anonymous, ed. Trace elements in human nutrition and health. World Health Organization; 49-71.
74. Clugston G, Beaudry M, Delange F. 1996 Iodine-induced thyrotoxicosis. 347: 1051.